VivoSeq
Metabolic & Endocrine

Obesity

335

Pipeline Programs↗

189

Active Trials↗

109

Companies Involved↗

Obesity is a highly competitive landscape with 335 programs across 109 companies. The most active players are Beijing QL Biopharmaceutical Co.,Ltd, Hangzhou Sciwind Biosciences Co., Ltd., MBX Biosciences. 77 therapies are approved with 50 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

91/100

Pipeline Velocity

90/100

Mech. Concentration

2/100

Completion Rate

85/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

B

Beijing QL Biopharmaceutical Co.,Ltd

2 programs

Phase 1H

Hangzhou Sciwind Biosciences Co., Ltd.

1 program

Phase 1M

MBX Biosciences

1 program

Phase 1E

ERX Pharmaceuticals

1 program

Phase 1T

Tonghua Dongbao Pharmaceutical Co.,Ltd

1 program

Phase 1C

Corbus Pharmaceuticals Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical55

Isoniazid

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Etomidate

Pfizer

Rimonabant

Sanofi

Quercetin

Mayo Clinic

Ergocalciferol

Alnylam Pharmaceuticals

Phase 166

Oxytocin

Retrophin

Ghrelin

University of Aarhus

GLP-1

Rigshospitalet, Denmark

Xenon

Nobilis Therapeutics Inc.

AZD1402

AstraZeneca

Phase 287

Pemvidutide

Altimmune

Onabotulinumtoxina

Vitae Pharmaceuticals Inc., an Allergan affiliate

Clomiphene Citrate

Ferring

Salsalate

Joslin Diabetes Center

Nabilone

Bausch Health Americas, Inc.

Phase 350

Orforglipron

Eli Lilly

Survodutide

Boehringer Ingelheim

Retatrutide

Eli Lilly

Topiramate

Wim Janssens

Metformin Hydrochloride

Boehringer Ingelheim

Approved77

Dapagliflozin

AstraZeneca

Misoprostol

Pfizer

Cefazolin

Baxter Healthcare Corporation

Bupropion

Glaxo Dba Glaxosmithkline

Acarbose

Bayer

Analysis

Modality Breakdown

92%

Small molecule

314 of 341 classified programs — the dominant modality here.

8%ALL OTHERSPeptide216%Monoclonal antibody51%Antibody–drug conjugate1<1%

Small molecule leads; the ring shows all 341 classified programs, each share of the total. Modality classified for 91% of 393 pipeline programs.

Analysis

Trial Status

457

clinical trials

Completed211 · 46%
Recruiting99 · 22%
Not yet recruiting45 · 10%
Active, not recruiting39 · 9%
Terminated19 · 4%
Unknown status18 · 4%
Other26 · 6%

Clinical Trials

Trial Activity

457 trials

Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT07293325·66 enrolled
Subcutaneously Administered MD-18 for the Treatment of Obesity and Diabetes
Recruiting·CCohen Global, Ltd.·Phase 1·NCT06739707·54 enrolled
A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults
Recruiting·Regeneron logoRegeneron·Phase 3·NCT07220772·4 enrolled
Vancomycin Dose Optimization in Obesity
Recruiting·UUniversity of Michigan·Phase 1·NCT06601257·24 enrolled
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
Recruiting·VVA Office of Research and Development·Phase 2·NCT06745063·50 enrolled
Prevention of Progression of Prediabetes, Obesity and CV Risk
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT06446531·64 enrolled
LIROH - Liraglutide for Obesity in HIV
Recruiting·—·Phase 4·NCT06438146·40 enrolled
Crocus Sativus Tepals Water Extract in Obesity and Prediabetes
Recruiting·UUniversity of Primorska·Phase 1·NCT07261475·20 enrolled
Levothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity.
Recruiting·FFundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud·Phase 3·NCT07332273·286 enrolled
Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity
Recruiting·KKorea University Anam Hospital·Phase 4·NCT06782139·30 enrolled
A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity
Recruiting·CCorbus Pharmaceuticals Inc.·Phase 1·NCT07310901·252 enrolled
Effect of Triticum Aestivum on Appetite, Ghrelin, Leptin, Adiponectin Hormonal Axis in Patients With Obesity
Recruiting·CCoordinación de Investigación en Salud, Mexico·Phase 3·NCT06496100·38 enrolled
Evaluation of Milk Polar Lipids in Dyslipidemic Adults With Abdominal Obesity
Recruiting·UUniversity of Connecticut·Phase 1·NCT05700916·130 enrolled
Evaluating Anti-Obesity Medications 6 Months After Metabolic Surgery
Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 4·NCT07163650·60 enrolled
First in Human Study in Subjects With Obesity, But Otherwise Healthy
Recruiting·NNeuroBo Pharmaceuticals Inc.·Phase 1·NCT06252220·139 enrolled
Page 1 of 31

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)